Details for New Drug Application (NDA): 019591

✉ Email this page to a colleague

NDA 019591 describes LARIAM, which is a drug marketed by Roche and is included in one NDA. Additional details are available on the LARIAM profile page.

The generic ingredient in LARIAM is mefloquine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mefloquine hydrochloride profile page.

Summary for 019591

Tradename:	LARIAM
Applicant:	Roche
Ingredient:	mefloquine hydrochloride
Patents:	0

Medical Subject Heading (MeSH) Categories for 019591

Antimalarials

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	250MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	May 2, 1989	TE:		RLD:	Yes

Expired US Patents for NDA 019591

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	LARIAM	mefloquine hydrochloride	TABLET;ORAL	019591-001	May 2, 1989	4,579,855	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.